SARS-CoV-2 and complement therapeutics studies
• Eculizumab (Soliris) in COVID-19 infected patients (SOLID-C19)
• Alexion to study Ultomiris for COVID-19 treatment
• The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
• InflaRx starts dosing COVID-19 patients in Europe
• Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
SARS-CoV-2 and complement literature
• Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases
• Coronaviruses hijack the complement system
• Complement as a target in COVID-19?
• Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis
• Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV
• Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV
SARS-CoV-2 and thromboinflammation/lung injury literature
• Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach
• Thrombomodulin in disseminated intravascular coagulation and other critical conditions - a multi-faceted anticoagulant protein with therapeutic potential:
• Soluble thrombomodulin Increases in patients with disseminated intravascular coagulation and in those with multiple organ dysfunction syndrome after trauma: role of neutrophil elastase
• Thrombomodulin favors leukocyte microvesicle fibrinolytic activity, reduces NETosis and prevents septic shock-induced coagulopathy in rats